Phage therapy added to usual care for staph-infected diabetic foot ulcers
Tests a bacteriophage treatment on diabetic foot ulcers infected with Staphylococcus aureus.
Key facts
- Who runs it
- Centre Hospitalier Universitaire de Nīmes
- Where
- France7 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus
- Status
- Not yet recruiting
- Phase
- Phase 1/2
- People taking part
- 60 people, planned
- Started
- 1 Sept 2026
- Expected to end
- Nov 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Topical anti-Staphylococcus bacteriophage therapy
- Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy
- Record updated
- 20 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 or type 2 diabetes who have an infected foot wound with S. aureus. It compares a phage cocktail put on the wound with a placebo, both added to standard treatment.
- Age
- 18 years and older.
- Sex
- All sexes.
- Disease stage
- A nerve-damage (neuropathic) foot wound below the ankle, present for >2 weeks, with a surface area ≥ 0,5 cm2. SINBAD class S (0 or 1), I (0 or 1), N (1), B (1), A (0 or 1), D (1). IWGDF/IDSA grade 2 or 3 infection with no bone infection. No poor blood flow, or only non-critical: ankle arterial pressure > 50 mm Hg, toe systolic pressure > 30 mm Hg, or TcpO2 > 30 mm Hg.
- Earlier treatment
- No other trial in the past three months.
- Biomarker or test result
- The wound must be infected by S. aureus (MSSA or MRSA), alone or with other bacteria, up to 3 bacteria in total. A phagogram test must show the strains respond to at least one phage (PP1493 and/or PP1815). Negative pregnancy test before treatment.
Main reasons for not taking part
- Bone infection (osteomyelitis) or joint inflammation (arthritis) linked to the wound
- Wound not infected by S. aureus, or infected by more than 3 bacteria
- Pregnant, giving birth or breastfeeding, or planning pregnancy during treatment and 1 month after
- Not willing to use effective birth control during and 1 month after the study drug
- Under guardianship or judicial protection
The registry criteria, word for word
Show all 29 criteriaShow less
Other criteria
- Participant pre-inclusion criteria:
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient is at least 18 years old
- The patient has type 1 or type 2 diabetes
- The patient is hospitalized/consulting in a participating centre
- The patient has a wound below the ankle that has be evolving for >2 weeks
- The patient has a neuropathic foot wound, classified S (0 or 1), I (0 or 1), N (1), B (1), A (0 or1) and D (1) according to the SINBAD classification,; without ischaemia or with non-critical ischaemia defined by: ankle arterial pressure > 50 mm Hg or toe systolic arterial pressure > 30 mm Hg or TcpO2 > 30 mm Hg ); with a surface area ≥ 0,5 cm2; With IWGDF/IDSA grade 2 or 3 infection without osteomyelitis (normal radiography*)
- Females of childbearing potential or Sexually active males with partner of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control (oral, transdermal, systemic or implant contraception birth control, intrauterine devices) for 1 month after the last study drug administration
- Negative pregnancy test must be obtained before starting any experimental drug
- Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months); Participant final inclusion criteria:
- The patient has a neuropathic foot wound:; Classified S (0 or 1), I (0 or 1), N (1), B (1), A (0 or1) and D (1) according to the SINBAD classification,
- without ischaemia or with non-critical ischaemia defined by: ankle arterial pressure > 50 mm Hg or toe systolic arterial pressure > 30 mm Hg or TcpO2 > 30 mm Hg )
- with a surface area ≥ 0,5 cm2; With IWGDF/IDSA grade 2 or 3 infection without osteomyelitis
- The patient's wound is monoinfected by methicillin-resistant or susceptible S. aureus (MSSA or MRSA ), or infected by MSSA or MRSA and other bacteria (a total of 3 bacteria when accounting for MSSA or MRSA)
- The Phagogram of the patient demonstrated that the strains are susceptible to at least one phage(PP1493 and/or PP1815); Participant pre-exclusion criteria:
- The patient is participating in, or has participated in over the past three months, another trial
- The patient is participating in, or has participated in over the past three months, another study that may interfere with the results or conclusions of this study
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection, or is an adult under guardianship
- It is impossible to correctly inform the patient
- The patient refuses to sign the consent
- The patient is pregnant, parturient or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and 1 month after the last administration of study drug
- Women/Men refusing to use an effective contraception during and1 month after the last administration of study drug; Participant final exclusion criteria:
- The patient refuses to participate to the study
- The patient is pregnant, parturient or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and 1 month after the last administration of study drug
- Women/Men refusing to use an effective contraception during and1 month after the last administration of study drug
- Patients with diabetic foot wounds associated with clinical or radiographic signs of arthritis or osteomyelitis*
- Patient is not infected by S. aureus or infected by more than 3 bacteria even if the culture isolates a S. aureus
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objective of this study is to compare the efficacy of standard treatment associated with a topical anti-staphylococcal bacteriophage cocktail versus standard treatment plus placebo for diabetic foot ulcers monoinfected by methicillin-resistant or susceptible S. aureus (MRSA or MSSA) as measured by the relative reduction in wound surface area (%) at 12 weeks.
The 2 groups in the trial
- Phage therapyTreatment being tested
Patients randomized to this arm will have phage therapy. Intervention: Topical anti-Staphylococcus bacteriophage therapy
Treatment: Topical anti-Staphylococcus bacteriophage therapy
- PlaceboPlacebo, for comparison
Patients randomized to this arm will have placebo therapy anologous to that of the experimental arm. Intervention: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy
Treatment: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Comparison of the Efficacy of Standard Treatment Associated With Phage Therapy Versus Standard Treatment Plus Placebo for Diabetic Foot Ulcers Monoinfected by Staphylococcus Aureus: a Randomized, Multi-centre, Controlled, 2-parallel-group, Double-blind, Superiority Trial
- Plain-language title
- Phage therapy added to usual care for staph-infected diabetic foot ulcersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 20 March 2026